COMP <GO>
ALXO vs CUE // EV/EBITDA & P/E VALUATION
ALX Oncology Holdings Inc. (NASDAQ) VS. Cue Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: ALXO 1
— CUE 1
■ METRIC PARITY
LAST: $1.22 (0.00%) • MKT CAP: $152.4M
valuation
—
LAST: $20.87 (-2.70%) • MKT CAP: $155.8M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALXO VS. CUE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALXO | CUE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -14.03% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 4/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.4 | 46.7 | +0.74 | ALXO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $152.4M | $155.8M | -$3.4M | CUE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALXO REV | CUE REV | ALXO GROSS % | CUE GROSS % | ALXO FCF | CUE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $27.5M | — | — | -$84.4M | -$21.9M |
| FY 2024 | $0 | $9.3M | — | — | -$122.4M | -$36.4M |
| FY 2023 | $0 | $5.5M | — | — | -$130.4M | -$40.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALXO // BETA —
CUE // BETA —